Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

Martinez-Marti, A; Felip, E; Matito, J; Mereu, E; Navarro, A; Cedres, S; Pardo, N; de Castro, AM; Remon, J; Miquel, JM; Guillaumet-Adkins, A; Nadal, E; Rodriguez-Esteban, G; Arques, O; Fasani, R; Nuciforo, P; Heyn, H; Villanueva, A; Palmer, HG; Vivan

Felip, E (reprint author), Vall dHebron Univ Hosp, Dept Med Oncol, P Vall dHebron 119-129, Barcelona 08035, Spain.; Vivancos, A (reprint author), Vall dHebron Inst Oncol, Canc Genom Grp, P Vall dHebron 119-129, Barcelona 08035, Spain.

ANNALS OF ONCOLOGY, 2017; 28 (10): 2451

Abstract

Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索